- Home
- NYC vs CODX Comparison
NYC vs CODX Comparison
Compare NYC & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- CODX
- Stock Information
- Founded
- NYC 2013
- CODX 2013
- Country
- NYC United States
- CODX United States
- Employees
- NYC N/A
- CODX N/A
- Industry
- NYC Real Estate
- CODX Medical/Dental Instruments
- Sector
- NYC Finance
- CODX Health Care
- Exchange
- NYC Nasdaq
- CODX Nasdaq
- Market Cap
- NYC 23.8M
- CODX 23.3M
- IPO Year
- NYC N/A
- CODX 2017
- Fundamental
- Price
- NYC $8.80
- CODX $0.80
- Analyst Decision
- NYC
- CODX Hold
- Analyst Count
- NYC 0
- CODX 1
- Target Price
- NYC N/A
- CODX $1.50
- AVG Volume (30 Days)
- NYC 6.3K
- CODX 332.5K
- Earning Date
- NYC 11-12-2024
- CODX 03-13-2025
- Dividend Yield
- NYC N/A
- CODX N/A
- EPS Growth
- NYC N/A
- CODX N/A
- EPS
- NYC N/A
- CODX N/A
- Revenue
- NYC $62,060,000.00
- CODX $7,321,012.00
- Revenue This Year
- NYC N/A
- CODX N/A
- Revenue Next Year
- NYC $3.18
- CODX N/A
- P/E Ratio
- NYC N/A
- CODX N/A
- Revenue Growth
- NYC N/A
- CODX 57.16
- 52 Week Low
- NYC $5.46
- CODX $0.67
- 52 Week High
- NYC $10.91
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- NYC 50.53
- CODX 48.28
- Support Level
- NYC $8.67
- CODX $0.71
- Resistance Level
- NYC $9.24
- CODX $0.88
- Average True Range (ATR)
- NYC 0.54
- CODX 0.10
- MACD
- NYC -0.01
- CODX 0.01
- Stochastic Oscillator
- NYC 49.28
- CODX 31.25
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.